Idrinol injection solution 100mg / ml, 5ml No. 10

• as part of the complex therapy of coronary heart disease (angina pectoris, myocardial infarction);

• chronic heart failure, dyshormonal cardiomyopathy;

• as part of complex therapy for acute disorders of cerebral circulation (ischemic stroke, cerebrovascular insufficiency);

• decreased performance, physical stress (including among athletes);

• withdrawal syndrome in chronic alcoholism (in combination with specific therapy);

• hemophthalmos and retinal hemorrhages of various etiologies, thrombosis of the central retinal vein and its branches, retinopathy of various etiologies (diabetic, hypertensive).

Due to the possibility of the development of an exciting effect, the drug is recommended to be used in the first half of the day.
Cardiovascular diseases
As part of complex therapy - intravenously 500 mg - 1.0 g (5-10 ml solution for intravenous and parabulbar administration 100 mg / ml), applying the entire dose at once or dividing it into 2 injections. The course of treatment is 10-14 days. Repeated courses (usually 2-3 times a year) - on the recommendation of a doctor.
Cerebral circulation disorders
In the acute phase, cerebrovascular accidents are administered intravenously, 500 mg (5 ml solution for intravenous and parabulbar administration, 100 mg / ml) 1 time per day for 10 days.
Reduced performance, physical stress (including in athletes)
For mental and physical exertion (including athletes), intravenous administration of 500 mg (5 ml of a solution for intravenous and parabulbar administration of 100 mg / ml) is prescribed once a day. The course of treatment is 10-14 days.
Withdrawal syndrome in chronic alcoholism (in combination with specific therapy)
With withdrawal syndrome, 500 mg is administered intravenously (5 ml of solution for intravenous and parabulbar administration of 100 mg / ml) 2 times a day. The course of treatment is 10-14 days.
Ophthalmopathology(hemophthalmus and retinal hemorrhages of various etiologies, thrombosis of the central retinal vein and its branches, retinopathy of various etiologies (diabetic, hypertensive). within 10 days, including as part of a combination therapy.

1 ml of solution contains:
Active substance : meldonium dihydrate without adsorbed moisture - 100 mg (in terms of anhydrous meldonium - 80.21 mg);
Excipients : water for injection.

• hypersensitivity to drug components;

• increased intracranial pressure (with impaired venous outflow and intracranial tumors);

• age up to 18 years (efficacy and safety have not been established).

Precautions : liver and / or kidney disease.

Trade name of the drug : IdrinolЃ

International Non-Proprietary Name (INN) : Meldonium

Dosage form : solution for intravenous and parabulbar administration

Composition : 1 ml of solution contains:
Active substance : meldonium dihydrate without adsorbed moisture - 100 mg (in terms of anhydrous meldonium - 80.21 mg);
Excipients : water for injection.

Description : clear colorless liquid

Pharmacotherapeutic group : metabolic agent.
ATX code —01?¬

Pharmacological properties
Pharmacodynamics
Meldonium is a structural analogue of gamma-butyrobetaine, a substance that is present in every cell of the human body. Meldonium inhibits gamma-butyrobetaine hydroxygenase, reduces the synthesis of carnitine and the transport of long-chain fatty acids through the cell membranes, prevents the accumulation of activated forms of under-oxidized fatty acids in cells - derivatives of acylcarnicine and acylcoenzyme A. transport of adenosine triphosphoric acid (ATP). At the same time, it activates glycolysis, which proceeds without additional oxygen consumption. As a result of a decrease in the concentration of carnitine, gamma-butyrobetaine, which has vasodilating properties, is intensively synthesized.The mechanism of action determines the variety of its pharmacological effects: increased efficiency, reduced symptoms of mental and physical stress, activation of tissue and humoral immunity, cardioprotective effect. In the case of acute ischemic damage to the myocardium, it slows down the formation of the necrosis zone and shortens the rehabilitation period. In case of heart failure, it improves myocardial contractility, increases exercise tolerance, and reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral circulation, it improves blood circulation in the ischemic focus. Effective in case of vascular pathology of the fundus. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism during the period of abstinence.reduction of symptoms of mental and physical stress, activation of tissue and humoral immunity, cardioprotective effect. In the case of acute ischemic damage to the myocardium, it slows down the formation of the necrosis zone and shortens the rehabilitation period. In case of heart failure, it improves myocardial contractility, increases exercise tolerance, and reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral circulation, it improves blood circulation in the ischemic focus. Effective in case of vascular pathology of the fundus. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism during the period of abstinence.reduction of symptoms of mental and physical stress, activation of tissue and humoral immunity, cardioprotective effect. In the case of acute ischemic myocardial damage, it slows down the formation of the necrosis zone and shortens the rehabilitation period. In case of heart failure, it improves myocardial contractility, increases exercise tolerance, and reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral circulation, it improves blood circulation in the ischemic focus. Effective in case of vascular pathology of the fundus. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism during the period of abstinence.In the case of acute ischemic myocardial damage, it slows down the formation of the necrosis zone and shortens the rehabilitation period. In case of heart failure, it improves myocardial contractility, increases exercise tolerance, and reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral circulation, it improves blood circulation in the ischemic focus. Effective in case of vascular pathology of the fundus. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism during the period of abstinence.In the case of acute ischemic myocardial damage, it slows down the formation of the necrosis zone and shortens the rehabilitation period. In case of heart failure, it improves myocardial contractility, increases exercise tolerance, and reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral circulation, it improves blood circulation in the ischemic focus. Effective in case of vascular pathology of the fundus. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism during the period of abstinence.In acute and chronic ischemic disorders of cerebral circulation, it improves blood circulation in the ischemic focus. Effective in case of vascular pathology of the fundus. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism during the period of abstinence.In acute and chronic ischemic disorders of cerebral circulation, it improves blood circulation in the ischemic focus. Effective in case of vascular pathology of the fundus. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism during the period of abstinence.

Pharmacokinetics The
maximum plasma concentration is reached immediately after administration.
It is metabolized in the body with the formation of two main metabolites, which are excreted by the kidneys. The half-life is 3-6 hours.

Indications for use

• as part of the complex therapy of coronary heart disease (angina pectoris, myocardial infarction);

• chronic heart failure, dyshormonal cardiomyopathy;

• as part of complex therapy for acute disorders of cerebral circulation (ischemic stroke, cerebrovascular insufficiency);

• decreased performance, physical stress (including among athletes);

• withdrawal syndrome in chronic alcoholism (in combination with specific therapy);

• hemophthalmos and retinal hemorrhages of various etiologies, thrombosis of the central retinal vein and its branches, retinopathy of various etiologies (diabetic, hypertensive).

Contraindications

• hypersensitivity to drug components;

• increased intracranial pressure (with impaired venous outflow and intracranial tumors);

• age up to 18 years (efficacy and safety have not been established).

Precautions : liver and / or kidney disease.

Application during pregnancy and lactation The
safety of the drug during pregnancy has not been proven. In order to avoid possible adverse effects on the fetus, the drug should not be prescribed during pregnancy.
It is not known whether the drug is excreted in breast milk. If it is necessary to use the drug IdrinolЃ during lactation, breastfeeding should be discontinued.

Method of administration and dosage
Due to the possibility of developing an exciting effect, the drug is recommended to be used in the morning.
Cardiovascular diseases
As part of complex therapy - intravenously 500 mg - 1.0 g (5-10 ml solution for intravenous and parabulbar administration 100 mg / ml), applying the entire dose at once or dividing it into 2 injections. The course of treatment is 10-14 days. Repeated courses (usually 2-3 times a year) - on the recommendation of a doctor.
Cerebral circulation disorders
In the acute phase, cerebrovascular accidents are administered intravenously, 500 mg (5 ml solution for intravenous and parabulbar administration, 100 mg / ml) 1 time per day for 10 days.
Reduced performance, physical stress (including in athletes)
For mental and physical exertion (including athletes), intravenous administration of 500 mg (5 ml of a solution for intravenous and parabulbar administration of 100 mg / ml) is prescribed once a day. The course of treatment is 10-14 days.
Withdrawal syndrome in chronic alcoholism (in combination with specific therapy)
With withdrawal syndrome, 500 mg is administered intravenously (5 ml of solution for intravenous and parabulbar administration of 100 mg / ml) 2 times a day. The course of treatment is 10-14 days.
Ophthalmopathology(hemophthalmus and retinal hemorrhages of various etiologies, thrombosis of the central retinal vein and its branches, retinopathy of various etiologies (diabetic, hypertensive). within 10 days, including as part of a combination therapy.

Side effect
From the side of the cardiovascular system : rarely - tachycardia, decrease or increase in blood pressure.
From the side of the central nervous system : rarely - psychomotor agitation.
From the digestive system : rarely - dyspeptic disorders.
Allergic reactions : rarely - itching, rash, hyperemia of the skin, angioedema; very rarely - eosinophilia.
Others : very rarely - general weakness.

Overdose
Symptoms : a decrease in blood pressure, accompanied by headache, tachycardia, dizziness and general weakness.
Treatment : symptomatic.

Interaction with other drugs
Can be combined with antianginal drugs, anticoagulants, antiplatelet agents, antiarrhythmics, diuretics, bronchodilators. Strengthens the action of cardiac glycosides. Due to the possible development of moderate tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-blockers, antihypertensive drugs and peripheral vasodilators.

Special instructions
IdrinolЃ is not a first-line drug for acute coronary syndrome. Influence on the ability to drive vehicles and mechanisms. There are no data on the adverse effects of IdrinolЃ on the rate of psychomotor reactions.

Release form
Solution for intravenous and parabulbar administration of 100 mg / ml.
5 ml in colorless glass ampoules.
5 ampoules in a blister strip packaging. 1 or 2 blister packs together with instructions for use in a cardboard box.

Storage conditions
List B. At a temperature not higher than 25 ? C. Do not freeze.
Keep out of the reach of children.

Shelf life is
3 years. Do not use after the expiration date printed on the package.

Terms of dispensing from pharmacies
Prescription.

Manufacturer :
CJSC 'FarmFirma' Sotex
141345, Russia, Moscow region, Sergiev Posad municipal district, rural settlement Bereznyakovskoye, pos. Belikovo, 11

Marketing authorization holder :
Sotex PharmFirma CJSC.
Consumer claims should be sent to the manufacturer's address